Related Experiment Video
Updated: Feb 27, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both
Jeffrey D Bjorge1,2, Andy Pang1,2, Donald J Fujita1,2
1Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Abstract:
RNA interference has been used to dissect the importance of individual gene products in various human disease processes, including cancer. Small-interfering RNA, or siRNA, is one of the tools utilized in this regard, but specially-designed delivery agents are required to allow the siRNA to gain optimal access to the cell interior. Our laboratory has utilized two different siRNA-binding delivery peptides containing a polyarginine core, and modified by myristoylation and targeting motifs (iRGD or Lyp-1). A third peptide was designed to assist with endosomal release. Various ratios of the peptides and siRNA were combined and assayed for the ability to form stable complexes, and optimized ratios were determined. The complexes were found to form particles, with the majority having a diameter of 100-300 nm, as visualized by electron microscopy. These siRNA complexes have enhanced protection from nucleases present in serum, as compared to "naked" unprotected siRNA. The particles were internalized by the cells and could be detected in the cell cytoplasm by confocal fluorescence microscopy. In functional assays, peptide/siRNA complexes were shown to cause the knock down of corresponding targeted proteins. The peptide with the LyP-1 targeting motif was more effective at knockdown in MDA-MB-231 breast cancer cells than the peptide with the iRGD motif. Inclusion of the endosomal release peptide in the complexes greatly enhanced the peptide/siRNA effects. Peptide/siRNA complexes simultaneously targeting Stat3 and c-Myc caused a marked reduction in anchorage-independent growth, a property correlated with tumorigenicity. This study demonstrates the ability of a peptide-based siRNA-delivery system to deliver siRNA into breast cancer cells and cause both protein knockdown and suppression of the malignant phenotype. Such peptide complexes are likely to become highly useful siRNA-delivery vehicles for the characterization, and potentially for the treatment, of human cancer.
Insights
Researchers developed peptide-based delivery systems for small-interfering RNA (siRNA) to target cancer cells. These complexes effectively deliver siRNA, reduce protein levels, and inhibit tumor growth, showing promise for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Nanotechnology
Background:
- RNA interference (RNAi) is crucial for studying gene function in diseases like cancer.
- Small-interfering RNA (siRNA) requires specialized delivery agents for cellular uptake.
- Existing delivery methods face challenges in cellular interior access.
Purpose of the Study:
- To develop and optimize peptide-based delivery systems for siRNA in cancer research.
- To evaluate the efficacy of targeted peptide-siRNA complexes in breast cancer cells.
- To assess the potential of these complexes for therapeutic applications in cancer treatment.
Main Methods:
- Designed and synthesized novel siRNA-binding peptides with targeting (iRGD, Lyp-1) and endosomal release motifs.
- Formulated stable peptide/siRNA complexes, optimizing ratios and characterizing particle size (100-300 nm) via electron microscopy.
- Assessed nuclease resistance, cellular uptake (confocal microscopy), protein knockdown, and functional effects on cancer cell growth (MDA-MB-231).
Main Results:
- Optimized peptide/siRNA complexes formed stable nanoparticles with enhanced serum nuclease protection.
- Complexes were efficiently internalized by breast cancer cells and localized in the cytoplasm.
- Lyp-1 targeted peptide complexes showed superior knockdown in MDA-MB-231 cells; endosomal release peptide significantly boosted efficacy.
- Simultaneous targeting of Stat3 and c-Myc suppressed anchorage-independent growth, indicating reduced tumorigenicity.
Conclusions:
- Peptide-based siRNA delivery systems effectively deliver siRNA into breast cancer cells.
- These complexes achieve significant protein knockdown and suppress the malignant phenotype.
- The developed peptide/siRNA complexes represent promising vehicles for cancer characterization and potential treatment.
More Related Videos
08:31Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted